Kisspeptin
ProtocolScheduling Kisspeptin alongside existing protocols, training, and lifestyle inputs requires understanding the compound's pharmacokinetic constraints and the cycle calendar. The upstream master regulator of GnRH neurons — driving the entire HPG axis from above. Studied for hypothalamic amenorrhea, fertility, and male sexual response. Daily timing relative to meals and training, weekly cycle structure, and integration with stack components on independent pathways are the three layers of the protocol calendar developed below.
Key Takeaways
Scheduling lens: Kisspeptin's ~28 min IV half-life via subq/iv (research) places it in the multi-daily-dosing bucket. Mechanism: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset. Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering. Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.
Protocol calendar planning for Kisspeptin is shaped by mechanism, pharmacokinetics, and operational reality. Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. This positions kisspeptin one step upstream of the entire reproductive endocrine axis. Effects on LH/FSH are tightly regulated and physiological — unlike exogenous HCG it does not bypass HPG feedback. The subsections below work through the daily timing patterns, the 8-12 week cycle structure with calibrated off-period, the stack scheduling principles, and the travel-and-disruption playbook.
Cycle length and off-cycle planning
Standard Kisspeptin cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.
Travel, schedule shifts, and continuity
Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any Kisspeptin protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most Kisspeptin schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.
Daily and weekly timing
Kisspeptin with a ~28 min IV half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 1-2x weekly SubQ, with consistency mattering more than the absolute clock time of any single dose.
The most-asked scheduling question for Kisspeptin in stack scheduling is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
Schedule design for Kisspeptin in periodised cycles starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
For protocol calendar scheduling, Kisspeptin is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
The most-asked scheduling question for Kisspeptin in off-time is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 100-200 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 60-200 mcg | 4–6 weeks initial cycle |
| Protocol focus | SubQ | 100-200 mcg | 1-2x weekly SubQ |
| Maintenance phase | SubQ | 70-200 mcg | Ongoing with periodic pauses |
Dose timing for Kisspeptin is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Kisspeptin stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.
- Kisspeptin + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Kisspeptin's mechanism in protocol / scheduling / cycling protocols.
- Kisspeptin + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Kisspeptin's mechanism in protocol / scheduling / cycling protocols.
- Kisspeptin + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Kisspeptin's mechanism in protocol / scheduling / cycling protocols.
- Kisspeptin + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Kisspeptin's mechanism in protocol / scheduling / cycling protocols.
Generally well tolerated. Used in fertility research safely. Affects gonadotropins — caution in hormone-sensitive conditions.
Lens-specific safety considerations for protocol / scheduling / cycling use of Kisspeptin: Generally well tolerated. Used in fertility research safely. Affects gonadotropins — caution in hormone-sensitive conditions. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Kisspeptin | Hypothalamic upstream regulator of GnRH | ~28 min IV | Protocol |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
Daily timing for Kisspeptin?
Cycle length and off-cycle period?
What if I miss a dose?
Stack timing relative to training and meals?
What should I look for in Kisspeptin sourcing and quality?
What is the regulatory status of Kisspeptin?
Start a Kisspeptin Protocol
Alukard provides physician-supervised peptide protocols with GMP-certified Kisspeptin and GMP-certified compounds with personalised cycle design.
Get ProtocolQuick Facts
- Molecular weight
- 1302 Da
- Sequence length
- 10 aa
- Half-life
- ~28 min IV
- WADA
- Not on prohibited list
- FDA
- Investigational
- Research
- Phase II in HSDD, fertility
Stack Partners
All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Kisspeptin unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Protocol / Scheduling / Cycling Protocol for Kisspeptin
Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.
HIPAA Compliant · GMP Certified · Physician Supervised